Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

HSDT vs DBVT vs ALKS vs STIM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
HSDT
Solana Company

Medical - Devices

HealthcareNASDAQ • US
Market Cap$89M
5Y Perf.-100.0%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1690.08T
5Y Perf.-59.3%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.83B
5Y Perf.+113.9%
STIM
Neuronetics, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$115M
5Y Perf.-9.6%

HSDT vs DBVT vs ALKS vs STIM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
HSDT logoHSDT
DBVT logoDBVT
ALKS logoALKS
STIM logoSTIM
IndustryMedical - DevicesBiotechnologyBiotechnologyMedical - Diagnostics & Research
Market Cap$89M$1690.08T$5.83B$115M
Revenue (TTM)$6M$0.00$1.56B$152M
Net Income (TTM)$-41M$-168M$153M$-37M
Gross Margin91.7%65.4%48.0%
Operating Margin-351.0%12.3%-19.4%
Forward P/E24.5x
Total Debt$0.00$22M$70M$90M
Cash & Equiv.$7M$194M$1.12B$34M

HSDT vs DBVT vs ALKS vs STIMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

HSDT
DBVT
ALKS
STIM
StockMay 20May 26Return
Solana Company (HSDT)1000.0-100.0%
DBV Technologies S.… (DBVT)10040.7-59.3%
Alkermes plc (ALKS)100213.9+113.9%
Neuronetics, Inc. (STIM)10090.4-9.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: HSDT vs DBVT vs ALKS vs STIM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ALKS leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Solana Company is the stronger pick specifically for growth and revenue expansion. DBVT also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
HSDT
Solana Company
The Growth Play

HSDT is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 10.6%, EPS growth 57.3%, 3Y rev CAGR 97.0%
  • 10.6% revenue growth vs DBVT's -100.0%
Best for: growth exposure
DBVT
DBV Technologies S.A.
The Income Pick

DBVT is the clearest fit if your priority is income & stability.

  • Dividend streak 0 yrs, beta 1.26
  • +100.5% vs HSDT's -99.0%
Best for: income & stability
ALKS
Alkermes plc
The Long-Run Compounder

ALKS carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.

  • -12.0% 10Y total return vs DBVT's -87.1%
  • Lower volatility, beta 1.00, Low D/E 3.8%, current ratio 3.55x
  • Beta 1.00, current ratio 3.55x
  • 9.8% margin vs HSDT's -6.8%
Best for: long-term compounding and sleep-well-at-night
STIM
Neuronetics, Inc.
The Growth Angle

STIM lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthHSDT logoHSDT10.6% revenue growth vs DBVT's -100.0%
Quality / MarginsALKS logoALKS9.8% margin vs HSDT's -6.8%
Stability / SafetyALKS logoALKSBeta 1.00 vs HSDT's 2.65
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)DBVT logoDBVT+100.5% vs HSDT's -99.0%
Efficiency (ROA)ALKS logoALKS5.4% ROA vs DBVT's -89.0%

HSDT vs DBVT vs ALKS vs STIM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

HSDTSolana Company
FY 2025
Product
76.6%$420,000
Product and Service, Other
23.4%$128,000
DBVTDBV Technologies S.A.

Segment breakdown not available.

ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
STIMNeuronetics, Inc.
FY 2025
Clinical Services Segment
58.3%$87M
Medical Device Segment
41.7%$62M

HSDT vs DBVT vs ALKS vs STIM — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGDBVT

Income & Cash Flow (Last 12 Months)

Evenly matched — HSDT and ALKS each lead in 3 of 6 comparable metrics.

ALKS and DBVT operate at a comparable scale, with $1.6B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to HSDT's -6.8%. On growth, HSDT holds the edge at +33.4% YoY revenue growth, suggesting stronger near-term business momentum.

MetricHSDT logoHSDTSolana CompanyDBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcSTIM logoSTIMNeuronetics, Inc.
RevenueTrailing 12 months$6M$0$1.6B$152M
EBITDAEarnings before interest/tax-$21M-$112M$212M-$27M
Net IncomeAfter-tax profit-$41M-$168M$153M-$37M
Free Cash FlowCash after capex-$17M-$151M$392M-$4M
Gross MarginGross profit ÷ Revenue+91.7%+65.4%+48.0%
Operating MarginEBIT ÷ Revenue-3.5%+12.3%-19.4%
Net MarginNet income ÷ Revenue-6.8%+9.8%-24.5%
FCF MarginFCF ÷ Revenue-2.7%+25.1%-2.6%
Rev. Growth (YoY)Latest quarter vs prior year+33.4%+28.2%+7.8%
EPS Growth (YoY)Latest quarter vs prior year+3.9%+91.5%-4.1%+23.8%
Evenly matched — HSDT and ALKS each lead in 3 of 6 comparable metrics.

Valuation Metrics

STIM leads this category, winning 2 of 3 comparable metrics.
MetricHSDT logoHSDTSolana CompanyDBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcSTIM logoSTIMNeuronetics, Inc.
Market CapShares × price$89M$1690.08T$5.8B$115M
Enterprise ValueMkt cap + debt − cash$82M$1690.08T$4.8B$171M
Trailing P/EPrice ÷ TTM EPS-1.20x-0.75x24.47x-2.81x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple17.01x
Price / SalesMarket cap ÷ Revenue14.87x3.95x0.77x
Price / BookPrice ÷ Book value/share0.16x0.65x3.25x4.16x
Price / FCFMarket cap ÷ FCF12.14x
STIM leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 8 of 9 comparable metrics.

ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-140 for STIM. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to STIM's 3.44x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs STIM's 4/9, reflecting strong financial health.

MetricHSDT logoHSDTSolana CompanyDBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcSTIM logoSTIMNeuronetics, Inc.
ROE (TTM)Return on equity-105.0%-130.2%+8.8%-139.8%
ROA (TTM)Return on assets-20.7%-89.0%+5.4%-27.1%
ROICReturn on invested capital-10.8%+18.9%-26.6%
ROCEReturn on capital employed-14.0%-145.7%+14.2%-28.5%
Piotroski ScoreFundamental quality 0–94474
Debt / EquityFinancial leverage0.13x0.04x3.44x
Net DebtTotal debt minus cash-$7M-$172M-$1.0B$56M
Cash & Equiv.Liquid assets$7M$194M$1.1B$34M
Total DebtShort + long-term debt$0$22M$70M$90M
Interest CoverageEBIT ÷ Interest expense-63.39x-189.82x32.30x-2.43x
ALKS leads this category, winning 8 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — DBVT and ALKS each lead in 3 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,165 today (with dividends reinvested), compared to $0 for HSDT. Over the past 12 months, DBVT leads with a +100.5% total return vs HSDT's -99.0%. The 3-year compound annual growth rate (CAGR) favors DBVT at 5.7% vs HSDT's -92.8% — a key indicator of consistent wealth creation.

MetricHSDT logoHSDTSolana CompanyDBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcSTIM logoSTIMNeuronetics, Inc.
YTD ReturnYear-to-date-28.2%+3.6%+23.8%+14.9%
1-Year ReturnPast 12 months-99.0%+100.5%+15.2%-64.4%
3-Year ReturnCumulative with dividends-100.0%+18.1%+13.2%-24.8%
5-Year ReturnCumulative with dividends-100.0%-68.3%+61.7%-87.3%
10-Year ReturnCumulative with dividends-100.0%-87.1%-12.0%-94.0%
CAGR (3Y)Annualised 3-year return-92.8%+5.7%+4.2%-9.1%
Evenly matched — DBVT and ALKS each lead in 3 of 6 comparable metrics.

Risk & Volatility

ALKS leads this category, winning 2 of 2 comparable metrics.

ALKS is the less volatile stock with a 1.00 beta — it tends to amplify market swings less than HSDT's 2.65 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 95.6% from its 52-week high vs HSDT's 0.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricHSDT logoHSDTSolana CompanyDBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcSTIM logoSTIMNeuronetics, Inc.
Beta (5Y)Sensitivity to S&P 5002.65x1.26x1.00x1.77x
52-Week HighHighest price in past year$258.50$26.18$36.60$4.85
52-Week LowLowest price in past year$1.61$7.53$25.17$0.80
% of 52W HighCurrent price vs 52-week peak+0.9%+75.3%+95.6%+34.1%
RSI (14)Momentum oscillator 0–10054.247.460.556.3
Avg Volume (50D)Average daily shares traded295K252K2.2M2.0M
ALKS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: DBVT as "Buy", ALKS as "Buy", STIM as "Buy". Consensus price targets imply 383.4% upside for STIM (target: $8) vs 31.5% for ALKS (target: $46).

MetricHSDT logoHSDTSolana CompanyDBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcSTIM logoSTIMNeuronetics, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$46.33$46.00$8.00
# AnalystsCovering analysts15287
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises00
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.5%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ALKS leads in 2 of 6 categories (Profitability & Efficiency, Risk & Volatility). STIM leads in 1 (Valuation Metrics). 2 tied.

Best OverallAlkermes plc (ALKS)Leads 2 of 6 categories
Loading custom metrics...

HSDT vs DBVT vs ALKS vs STIM: Key Questions Answered

8 questions · data-driven answers · updated daily

01

Is HSDT or DBVT or ALKS or STIM a better buy right now?

For growth investors, Solana Company (HSDT) is the stronger pick with 1057% revenue growth year-over-year, versus -5.

2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 5x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — HSDT or DBVT or ALKS or STIM?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +61.

7%, compared to -100. 0% for Solana Company (HSDT). Over 10 years, the gap is even starker: ALKS returned -12. 0% versus HSDT's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — HSDT or DBVT or ALKS or STIM?

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

00β versus Solana Company's 2. 65β — meaning HSDT is approximately 166% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 3% for Neuronetics, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — HSDT or DBVT or ALKS or STIM?

By revenue growth (latest reported year), Solana Company (HSDT) is pulling ahead at 1057% versus -5.

2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Solana Company grew EPS 57. 3% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, HSDT leads at 97. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — HSDT or DBVT or ALKS or STIM?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -679. 6% for Solana Company — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -351. 0% for HSDT. At the gross margin level — before operating expenses — HSDT leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — HSDT or DBVT or ALKS or STIM?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is HSDT or DBVT or ALKS or STIM better for a retirement portfolio?

For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

00)). Solana Company (HSDT) carries a higher beta of 2. 65 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -12. 0%, HSDT: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between HSDT and DBVT and ALKS and STIM?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HSDT is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; STIM is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

HSDT

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 1669%
  • Gross Margin > 55%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

STIM

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 28%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.